Acumen Pharmaceuticals Inc (ABOS)

Acumen Pharmaceuticals Inc (ABOS) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $143M; returns 1 day -3.9%, 1 week +17.2%, 1 year -6.2%.

Acumen Pharmaceuticals Inc. (ABOS) is a clinical-stage biopharmaceutical company focused on developing therapies for Alzheimer's disease. They are primarily focused on advancing sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble amyloid-beta oligomers (AβOs). As a clinical-stage company, Acumen does not currently have any revenue.

Groups ABOS belongs to

• Alzheimer's Disease
• Biotechnology
• Clinical Stage Biotech
• Clinical Stage
• Monoclonal Antibodies
• Healthcare
• Neuroscience
• Life Sciences
• CNS Disorders
• Biopharmaceutical
• Drug Discovery

ABOS financial model: income statement, cash flow and balance sheet